Support Alert

COVID-19 Therapeutic Alert

The UK-wide clinical commissioning policy has now been revised to reflect the availability of the nMAB sotrovimab (from the week commencing 20 December) and the current understanding of the likely impact of the Omicron variant on the efficacy of the combination nMAB casirivimab and imdevimab.

Further information on the updated policy and actions can be found in the alert.



Renew for 2022

Your dedication to patient care has made us proud during 2021.

That's why you can count on us to represent your interests and support your efforts every step of the way in 2022.